In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

The union government has reduced GST on three cancer drugs from 12% to 5%, following an earlier exemption from basic customs ...

Reuters Health Information, September 09, 2024 Will Tirzepatide Vials Help Patients ... significant progression-free survival over pembrolizumab in advanced PD-L1-positive NSCLC.

May 07, 2024--ImmunityBio, Inc. (NASDAQ: IBRX) announced today that the drug substance (DS) has been completed and successfully qualified for "fill finish" (filling vials and finishing packaging ...

After a median follow-up of 75 months, the 5-year OS was 86.6% in patients who received pembrolizumab (Keytruda) before and after surgery compared with 81.7% in those who received only neoadjuvant ...

Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery is unknown. In this phase 3 trial, we randomly ...

In the phase III study, ivonescimab achieved a median PFS of 11.14 months compared with 5.82 months with pembrolizumab, translating into a 49% reduction in the risk of progression or death (HR 0. ...

In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the ...

BARCELONA, Spain — Adding pembrolizumab to standard concurrent chemoradiotherapy (CCRT) significantly improves overall survival in patients with high-risk, locally advanced cervical cancer ...